fda warning compounded tirzepatide safety What Color Is with B12? vs FDA-Approved FDA issued a warning letter

The FDA resolved the national semaglutide shortage in February 2025, which legally ended the basis for widespread compounding under those exemptions

Obesity may induce the onset of other conditions leading to overt cardiovascular disease, such as glucose intolerance, dyslipidemia, impaired glucose tolerance and type 2 diabetes, hypertension, and kidney failure (Martin-Rodriguez et al., 2015

The timing of starting metformin may coincidentally overlap with the natural progression of these complications, leading patients to attribute vision changes to the medication rather than the disease process itself

However, researchers have compared the impact of both drugs from different studies and suggested that the higher doses (10mg and 15mg) of tirzepatide might reduce weight by 5.15kg more than 2mg of semaglutide

Surface-enhanced infrared absorption spectroscopy (SEIRAS) to probe monolayers of membrane proteins

The body is beginning to adjust to the semaglutide